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Background: Peroxisome proliferator-activated receptor gamma-2 gene (PPARγ2) rs1801282 (Pro12Ala) polymorphism
has been associated with lower risk of metabolic disturbance and atherosclerosis. The aim of this study was to analyze
the association between the Pro12Ala polymorphism and cardiometabolic risk factors in human immunodeficiency
virus (HIV)/Hepatitis C virus (HCV)-coinfected patients.
Methods: We carried out a cross-sectional study on 257 HIV/HCV coinfected patients. PPARγ2 polymorphism was
genotyped by GoldenGate® assay. The main outcome measures were: i) serum lipids (cholesterol, triglycerides,
high-density lipoprotein (HDL-C), low-density lipoprotein (LDL-C), LDL-C/HDL-C, and atherogenic index (AI));
ii) homeostatic model assessment (HOMA-IR) values; iii) serum adipokines (leptin, adiponectin, resistin, plasminogen
activator inhibitor-1(PAI-1), hepatic growth factor (HGF), and nerve growth factor (NGF)). Generalized Linear Models
(GLM) with gamma distribution (log-link) were used to investigate the association between PPARγ2 polymorphism and
continuous outcome variables. This test gives the differences between groups and the arithmetic mean ratio (AMR) in
continuous outcome variables between groups.
Results: The rs1801282 CG/GG genotype was associated with low values of cholesterol (adjusted arithmetic mean ratio
(aAMR) = 0.87 (95% of confidence interval (95% CI) = 0.79; 0.96); p = 0.004) and LDL-C (aAMR = 0.79 (95% CI = 0.68; 0.93);
p = 0.004). Furthermore, rs1801282 CG/GG was associated with low values of HOMA-IR (aAMR = 0.69 (95% CI = 0.49;
0.98); p = 0.038) among patients with significant liver fibrosis (F≥ 2). Moreover, rs1801282 CG/GG was also associated
with low serum values of hepatic growth factor (HGF) (aAMR = 0.61 (95% CI = 0.39; 0.94); p = 0.028), and nerve growth
factor (NGF) (aAMR = 0.47 (95% CI = 0.26; 0.84); p = 0.010). The serum levels of leptin, adiponectin, resistin, and PAI-1 did
not show significant differences.
Conclusions: The presence of PPARγ2 rs1801282 G allele (Ala variant) was associated with a protective cardiometabolic
risk profile versus CC genotype in HIV/HCV-coinfected patients. Thus, PPARγ2 rs1801282 polymorphism may play a
significant role in the development of metabolic disorders in HIV/HCV coinfected patients, and might have an
influence on the cardiovascular risk.
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The introduction of effective combination antiretroviral
therapy (cART) has dramatically reduced the mortality
and illness related to human immunodeficiency virus
(HIV) infection [1]. However, an increased risk of dyslip-
idemia, insulin resistance, and type 2 diabetes mellitus
(T2DM) has been described in human immunodeficiency
virus (HIV)-infected individuals who underwent cART
[2]. Furthermore, HIV/hepatitis C virus (HCV) coinfection
is associated with metabolic disturbance such as dyslipid-
emia, insulin resistance, and T2DM, which are also associ-
ated with an increased risk of cardiovascular disease [3].
These series of factors have increased the risk of cardio-
vascular diseases in patients with HIV/HCV coinfection in
cART era [4,5].
Peroxisome proliferator-activated receptor gamma (PPARγ)
is considered as a “key element” in the course of glucose
homeostasis, lipoprotein metabolism and vascular homeo-
stasis [6]. The most common polymorphism in PPARγ2
gene is the Pro12Ala (rs1801282) polymorphism, which
generates a cytosine-guanine exchange (CCA-to-GCA mis-
sense mutation), affecting the NH2-terminal residue that
defines the adipocyte-specific PPARγ2 isoform [7]. The
rs1801282 G allele (which encodes Ala) has been associ-
ated with lower risk of insulin resistance and T2DM
[8,9], hypertension [10], and lower value of carotid artery
intima-media thickness, protecting against early athero-
sclerosis [11-15]. Additionally, rs1801282 polymorphism
seems to have an influence on blood lipid levels in differ-
ent ways, according to the lipid fraction analyzed [16].
However, it has not been found an association between
Pro12Ala (rs1801282) polymorphism and metabolic syn-
drome [17]. In clinical trials with large numbers of
patients, the effect of Pro12Ala polymorphism on meta-
bolic disturbances remains controversial since Ala variant
has been related to unfavorable changes in serum choles-
terol [18], no improvement in lipid variables [19], im-
provement of plasma lipid levels [20], decreased risk of
developing hyperglycemia [21], increased BMI, waist-to-
hip ratio, and fasting glucose [22], and weight loss [23]. In
the Spanish population, the Ala12 allele was associated
with lower total triglycerides levels and increased insulin
sensitivity [24].
Probably, Pro12Ala polymorphism may act differently in
HIV/HCV coinfected patients due to the fact that HIV
proteins and antiretroviral drugs seem to negatively influ-
ence the adipocyte PPARγ expression [25-28]. Besides,
HIV/HCV coinfected patients have an intrinsic metabolic
deregulation, which may be enhanced by unhealthy habits
that are very pronounced in people coinfected with HIV
and HCV (smoking, drug abuse, alcohol, etc.) [29]. Thus,
the aim of our study was to analyze the association be-
tween the Pro12Ala polymorphism and cardiometabolic
risk in HIV/HCV coinfected patients.Patients and methods
Patients
We carried out a cross-sectional study in HIV/HCV-
coinfected patients from Hospital Gregorio Marañón
(Madrid, Spain) between September 2000 and July 2009.
The study was approved by the Institutional Review
Board and the Research Ethic Committee (“Comité de
Ética de la Investigación y de Bienestar Animal”) of the
Instituto de Salud Carlos III. This study was conducted
in accordance with the Declaration of Helsinki and pa-
tients gave their written consent for the study. All pa-
tients were European whites.
All subjects were HCV treatment-naive patients who
were potential candidates for HCV therapy and, in most
cases, underwent a liver biopsy. The inclusion criteria
were: detectable HCV-RNA by polymerase chain reac-
tion, negative hepatitis B surface antigen, availability of
DNA sample, no clinical evidence of hepatic decompen-
sation, no diabetes mellitus, and stable cART or no need
for cART. Patients with active opportunistic infections,
active drug and/or alcohol addiction, and other con-
comitant diseases were excluded.
A total of 293 HIV/HCV coinfected patients met the
inclusion criteria, but only 257 patients were available
for analysis: 11 patients were excluded due to genotyping
problems and 25 were discarded due to missing data (no
homeostatic model assessment (HOMA-IR) data (n = 23)
and no lipid data (n = 2)). Besides, only 207 patients had
liver biopsy data and 109 patients had an available sample
stored at −80°C for testing serum adipokines.
Epidemiological and clinical data
Medical records were used to obtain epidemiological
and clinical data when HCV therapy was started and/or
liver biopsy was performed.
The duration of HCV infection for patients with a his-
tory of intravenous drug use was estimated starting from
the first year they shared needles and other injection para-
phernalia, which are the most relevant risk practices for
HCV transmission [30]. For non-intravenous drug use
patients, we only included those patients for which the
initiation of their HCV infection could be determined with
certainty.
Biochemistry panel was measured using a fully auto-
mated clinical chemistry analyzer (Hitachi 912, Boehringer
Mannheim, Germany) in serum of fasting patients. The
collected data were total cholesterol (TC), triglycerides (TG)
and high-density lipoprotein (HDL-C). The low-density lipo-
protein (LDL-C) was calculated by Friedewald estimation
(LDL-C=TC – HDL-C – (TG/5)) [31]. The atherogenic risk
was estimated for each patient using the atherogenic index
(AI) (AI = (TC – HDL-C)/HDL-C). Non HDL-C was cal-
culated as TC minus HDL-C. The degree of IR was esti-
mated for each patient using the HOMA-IR method
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times fasting insulin (mU/l) divided by 22.5.
Liver biopsies were performed as previously described
[33]. Liver fibrosis was estimated according to Metavir
score. Fibrosis was scored as follows: F0, no fibrosis;
F1, portal fibrosis; F2, periportal fibrosis or rare portal-
portal septa; F3, fibrous septa with architectural distortion;
no obvious cirrhosis (bridging fibrosis); and F4, definite
cirrhosis.
Laboratory assays
Serum adipokines (leptin, adiponectin, resistin, plasminogen
activator inhibitor-1 (PAI-1), hepatic growth factor (HGF),
and nerve growth factor (NGF)) were measured by multi-
plex assay using Multiplex kit (LINCOplex™; LINCO
Research, St. Charles, Missouri, United States) in the
Luminex 100™ analyzer (Luminex Corporation, Austin, Texas,
United States), following manufacturer’s specifications.
Genomic DNA was extracted from peripheral blood
with Qiagen kit (QIAamp DNA Blood Midi/Maxi; Qiagen,
Hilden, Germany). DNA samples were genotyped at the
Spanish National Genotyping Center (CeGen; http://www.
cegen.org/) for the rs1801282 (C > G) SNP at PPARγ2
gene. Genotyping was performed by using GoldenGate®
assay with VeraCode® Technology (Illumina Inc. San
Diego, CA, USA). Moreover, we have also considered
other two SNPs that have recently been associated
with metabolic disturbances in HIV/HCV coinfected
patients: SLC30A8 rs13266634 [34] and ADIPOQ
rs2241766 [35]. These SNPs were selected from a review
of Staiger et al. about the T2DM risk genes and their
genetic variants in patients not infected with HIV and/
or HCV [36].
Outcome variables
i. Dyslipidemia: Serum concentration of TC, TG,
HDL-C, LDL-C, LDL-C/HDL-C, and AI.
ii. Insulin resistance: HOMA-IR values.
iii. Serum adipokines: levels of leptin, adiponectin,
resistin, PAI-1, HGF, and NGF.
Statistical analysis
All statistical tests were performed with the Statistical
Package for the Social Sciences (SPSS) 19.0 software
(IBM Corp., Chicago, USA). All p-values were two-tailed
and statistical significance was defined as p < 0.05.
For the description of the study population, p-values
were estimated with nonparametric tests: Mann–Whitney
U test was used for continuous variable and Chi-square
test for categorical variable.
For the genetic association study, the analysis was car-
ried out according to a dominant genetic model of G allele
(CC vs. CG/GG), which was the model that best fit to
our data. Univariate and multivariate Generalized LinearModels (GLM) with gamma distribution (log-link) were
used to investigate the association between PPARγ2 poly-
morphism and continuous outcome variables. This test
gives the differences between groups and the arithmetic
mean ratio (AMR) in continuous outcome variables be-
tween groups. All GLM tests were adjusted by the most
important clinical and epidemiological characteristics. We
included the SNP (Enter algorithm) and the most relevant
epidemiological and clinical characteristics (backward cri-
terion with a p-value for exit of 0.20). The covariables
used were gender, age, body mass index (BMI), acquired
immune deficiency syndrome, nadir CD4+ T-cells, un-
detectable HIV viral load (<50 copies/mL), time with
cART, cART with protease inhibitor, specific antiretroviral
drugs (saquinavir, efavirenz, ritonavir, tenofovir, thymidine
analogues (AZT, d4T), etc.), HCV genotype, HCV viral




Table 1 shows the main epidemiological and clinical char-
acteristics of the 257 non-diabetic HIV/HCV-coinfected
patients (191 men and 66 women).
The frequency of CG/GG genotype (Ala variant) in our
dataset was 13.2%, and was in accordance with minimum
allele frequency (MAF) listed on the NCBI SNP database,
where the frequency for CG/GG genotypes ranged from
12% to 25% (http://www.ncbi.nlm.nih.gov/projects/SNP/
snp_ref.cgi?rs=1801282). PPARγ2 polymorphism was in
Hardy-Weinberg equilibrium (p > 0.05) and displayed less
than 5% of missing values.
PPARγ2 polymorphism and lipid profile
Patients with rs1801282 CG/GG genotype (Ala variant) had
lower values of TC (p = 0.008), LDL-C (p = 0.005), LDL-C/
HDL-C ratio (p = 0.027), and AI (p = 0.031) than rs1801282
CC (Pro variant) carriers (Table 2). Furthermore, Ala vari-
ant was associated with low values of TC (adjusted AMR
(aAMR) = 0.87 ((95% of confidence interval (95% CI) =
0.79; 0.95); p = 0.004) and LDL-C (aAMR= 0.79 (95% CI =
0.68; 0.93); p = 0.004) (Table 2). Moreover, we evaluated
the cut-offs for serum lipids (TC ≥ 200 mg/dL, TG ≥
170 mg/dL, LDL-C ≥ 100 mg/dL, HDL-C ≤ 35 mg/dL,
LDL-C/HDL-C ≥ 3.0, and AI ≥ 3.5), but no statistically sig-
nificant results were found (data not shown).
PPARγ2 polymorphism and insulin resistance
Patients with rs1801282 CG/GG genotype had similar
HOMA-IR values than patients with rs1801282 CC geno-
type (Table 3). However, when patients were stratified by
liver fibrosis (F < 2 vs. F ≥ 2), rs1801282 CG/GG patients
with significant fibrosis (F ≥ 2) had lower HOMA-IR
values than rs1801282 CC carriers (p = 0.025) (Table 3).
Table 1 Clinical and epidemiological characteristics of all HIV/HCV coinfected patients stratified by PPARγ2 genotype
PPARγ2 polymorphism
All patients (n = 257) CC (n = 223) CG/GG (n = 34) p-value
Gender (male) 191 (74.3%) 165 (74.0%) 26 (76.5%) 0.758
Age (years) 40.9 (37.9; 44.7) 41.0 (37.9; 44.7) 40.1 (36.0; 44.7) 0.675
BMI (kg/m2) 22.5 (20.9; 24.7) 22.5 (20.9; 24.7) 22.6 (20.7; 24.3) 0.875
BMI ≥25 kg/m2 60 (23.4%) 54 (23.9%) 7 (20.6%) 0.674
HIV acquired by IVDU 219 (85_.2%) 191 (85.7%) 28 (82.4%) 0.785
Years since HCV infection 21.3 (16.6; 24.4) 21.6 (16.7; 24.6) 18.5 (16.1; 23.3) 0.149
Prior AIDS 74 (28.8%) 64 (28.7%) 10 (29.4%) 0.973
cART 215 (83.7%) 186 (83.4%) 29 (85.3%) 0.831
Time on cART (years) 4.8 (2.9; 7.8) 4.7 (2.7; 7.7) 4.9 (3.3; 8.7) 0.490
Current cART protocols
Any NRTIs + any PI 62 (24.1%) 51 (22.9%) 11 (32.4%) 0.229
Any NRTIs + PI + NNRTI 3 (1.2%) 2 (0.9%) 1 (2.9%) 0.301
Any NRTIs + any NNRTI 130 (50.6%) 114 (51.1%) 16 (47.1%) 0.659
Only NRTIs 20 (7.8%) 19 (8.5%) 1 (2.9%) 0.258
Specific antiretroviral drugs
Zidovudine 71 (7.6%) 63 (28.8%) 8 (23.5%) 0.566
Stavudine 66 (25.7%) 55 (25.4%) 11 (32.4%) 0.339
Didanosine 41 (16.0%) 35 (15.7%) 6 (17.6%) 0.772
Tenofovir 70 (27.2%) 59 (26.5%) 11 (32.4%) 0.472
Abacavir 43 (16.7%) 41 (18.4%) 2 (5.9%) 0.069
Efavirenz 76 (29.6%) 72 (32.3%) 4 (11.8%) 0.015
Ritonavir 47 (18.3%) 38 (17.0%) 9 (26.5%) 0.185
HIV markers
Nadir CD4+ T-cells (cells/μL) 208 (93; 314.5) 195 (92.5; 306) 257 (145; 364) 0.176
CD4+ T cells/μL 467 (341.7; 670.7) 467 (340; 660) 471 (368; 690) 0.678
HIV-RNA <50 copies/mL 76.6% (196/256) 77.5% (172/222) 70.6% (24/34) 0.377
HCV markers
HCV-genotype 1/4 72.7% (181/249) 72.1% (155/215) 76.5% (26/34) 0.594
HCV-RNA ≥500,000 UI/ml 75.6% (186/246) 74.5% (158/212) 82.4% (28/34) 0.324
Significant fibrosis (F ≥ 2) 47.8% (99/207) 46.7% (85/182) 56.0% (14/25) 0.383
Categorical variables are expressed in percentage (absolute count). Continuous variables are expressed in median (percentile 25; percentile 75). P-values were
estimated with nonparametric Mann–Whitney U test for continuous variable and Chi-square test for categorical variable.
Abbreviations: AIDS acquired immunodeficiency syndrome, BMI body mass index, cART combination antiretroviral therapy, HCV hepatitis C virus, HCV-RNA HCV
plasma viral load, HIV human immunodeficiency virus, HIV-RNA HIV plasma viral load, IVDU intravenous drug users, NNRTI no nucleoside analog reverse-transcriptase
inhibitors, NRTI nucleoside analog reverse-transcriptase inhibitors, PI protease inhibitors.
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tients with significant liver fibrosis (F ≥ 2), Ala variant was
associated with low values of HOMA-IR (aAMR= 0.69
(95% CI = 0.49; 0.98); p = 0.038) (Table 3). Moreover,
no statistically significant results were found for the cut-
offs of HOMA-IR (≥2.0, ≥2.5, ≥3.0, and ≥3.8) (data not
shown).
PPARγ2 polymorphism and serum adipokine levels
Rs1801282 CG/GG carriers had lower values of HGF
(p = 0.003) and NGF (p = 0.008) than rs1801282 CC (Alavariant) carriers (Table 4). When adjusted GLM analysis
was performed, Ala variant was associated with low
values of HGF (AMR = 0.61 (95% CI = 0.39; 0.94); p =
0.028), and NGF (AMR= 0.47 (95% CI = 0.26; 0.84); p =
0.010) (Table 4). However, we did not find any signifi-
cant association for adiponectin, leptin, PAI-1, and resis-
tin levels (Table 4).
Discussion
In this pilot study, rs1801282 G allele (Ala variant) was re-
lated to favorable cardiometabolic risk profile with lower
Table 2 Association between PPARγ2 CG/GG genotype (Ala variant) and serum lipids in HIV/HCV coinfected patients
CC CG/GG p-value(a) aAMR (95% CI) p-value(b)
TC (mg/dL) 156.0 (63.0) 139.0 (49.0) 0.008 0.87 (0.79; 0.95) 0.004
TG (mg/dL) 122.0 (49.0) 122.0 (27.0) 0.319 0.92 (0.81; 1.04) 0.163
LDL-C (mg/dL) 86.4 (54.1) 72.4 (36.0) 0.005 0.79 (0.68; 0.93) 0.004
HDL-C (mg/dL) 36.0 (18.0) 36.0 (12.0) 0.921 0.98 (0.89; 1.09) 0.734
LDL-C/HDL-C 2.1 (1.3) 1.8 (1.1) 0.027 0.86 (0.73; 1.01) 0.067
AI 2.7 (1.6) 2.5 (1.4) 0.031 0.87 (0.76; 1.01) 0.069
Values expressed as median [interquartile range = upper quartile (Q3) - lower quartile (Q1)] and adjusted arithmetic mean ratio (aAMR) [95% of confidence interval
(95% CI)]. Statistically significant differences are shown in bold. (a)P-values were calculated by generalized linear models (GLM) with gamma distribution (log-link).
(b)P-values were calculated by GLM with log-link adjusted by the most important clinical and epidemiological characteristics (see Statistical analysis section).
Abbreviations: HCV hepatitis C virus, HIV human immunodeficiency virus, TC total cholesterol, TG triglycerides, LDL-C low density lipoprotein, HDL-C high density
lipoprotein, LDL-C/HDL-C ratio of low density lipoprotein/high density lipoprotein, AI atherogenic index.
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patients with significant fibrosis (F ≥ 2), and adipokines
(HGF and NGF). However, no significant association was
found between rs1801282 polymorphism and metabolic
disturbance (serum lipids and HOMA-IR values higher
than cut-offs).
A recent meta-analysis has shown an inconclusive asso-
ciation between rs1801282 polymorphism and lipid profile
in HIV seronegative subjects [16]. This meta-analysis
suggests that, compared with rs1801282 CC genotype,
carriers of rs1801282 CG/GG genotype have significant
increased blood TC, and marginally significant increased
blood HDL-C in healthy male subjects [16]. Moreover,
there are only three articles published about PPARγ2
rs1801282 polymorphism in HIV infection [37-39], which
did not find any association of rs1801282 polymorphism
with lipodystrophy, lipid profile, and insulin sensitivity in
HIV-1-infected patients treated with cART [37-39]. In our
HIV/HCV coinfected patients, Ala variant carriers had
lower values of TC, LDL-C, LDL-C/HDL-C, and AI. In
fact, the severe dyslipidemia in these patients may be af-
fected by a large number of factors such as chronic hepa-
titis C, HIV infection itself, cART used, and body
composition changes [29], as well as the traditional factors
that increase atherosclerotic risk in the non–HIV-infected
population, including genetic factors, diet, alcohol, obesity
and inactivity. In our study, it seems clear the protective
effect PPARγ2 Ala variant on serum lipids, being able to
have a long-term protective effect on associated cardiovas-
cular disease. In this regard, PPARγ2 Ala variant has beenTable 3 Association between PPARγ2 CG/GG genotype (Ala va
CC CG/GG
All patients 2.1 (2.4) 1.7 (2.3)
Patients with F < 2 1.8 (1.8) 1.3 (1.5)
Patients with F ≥ 2 2.5 (3.3) 2.3 (1.9)
Values expressed as median [interquartile range = upper quartile (Q3) - lower quart
(95% CI)]. Statistically significant differences are shown in bold. (a)P-values were calc
(b)P-values were calculated by GLM with log-link adjusted by the most important cl
Abbreviations: HCV hepatitis C virus, HIV human immunodeficiency virus, HOMA hoassociated with a reduced risk of hypertension [10], early
atherosclerosis [12-15], coronary artery disease [40], and
myocardial infarction [41] in general population.
The majority of published data in non HIV-infected pa-
tients indicate the association of Ala variant with reduced
rates of insulin resistance and T2DM [8,9], although this
effect is influenced by genetic heterogeneity [42]. In our
study, we only found this favorable effect of Ala variant in
patients with significant fibrosis (F ≥ 2), who had the low-
est HOMA-IR values. Since approximately 50% of portal
insulin is cleared by the liver during first-past transit [43],
liver fibrosis might lead to impaired hepatic clearance of
insulin and, consequently, it could affect HOMA-IR
values. Therefore, rs1801282 polymorphism might play an
important role on alterations in insulin metabolism
secondary to significant fibrosis. However, the PPARγ2
rs1801282 polymorphism was not associated with the
HOMA-IR cutoffs that indicate IR. This lack of signifi-
cance might be due to the limited number of patients used
in the stratified analysis, or also to the possible distortive
effect of direct and indirect factors related to both HIV
and HCV infections, and cART [29]. Moreover, we must
also take in mind that our patients had a relatively low
BMI (22.5 kg/m2), possibly due to the fact that around
85% of our patients were IDUs. HIV infection and chronic
drug abuse both compromise nutritional status of patients
despite major advances in the HIV treatment [44], allow-
ing that HIV-positive IDUs had lower BMI.
PPARγ is involved in the regulation of adipogenesis,
lipid storage, and glucose metabolism [7]. The adiposeriant) and HOMA-IR in HIV/HCV coinfected patients
p-value(a) aAMR (95% CI) p-value(b)
0.839 0.89 (0.66; 1.20) 0.452
0.681 1.01 (0.61; 1.65) 0.988
0.025 0.69 (0.49; 0.98) 0.038
ile (Q1)] and adjusted arithmetic mean ratio (aAMR) [95% of confidence interval
ulated by generalized linear models (GLM) with gamma distribution (log-link).
inical and epidemiological characteristics (see Statistical analysis section).
meostatic model assessment.
Table 4 Association between PPARγ2 CG/GG genotype (Ala variant) and serum adipokines in HIV/HCV coinfected
patients
CC CG/GG p-value(a) aAMR (95% CI) p-value(b)
HGF (pg/mL) 1964.9 (2079.2) 1044.4 (1327.1) 0.003 0.61 (0.39; 0.94) 0.028
NGF (pg/mL) 9.48 (9.43) 6.16 (8.32) 0.008 0.47 (0.26; 0.84) 0.010
PAI-1 (pg/mL) 1474.9 (17338.2) 1363.1 (7366.9) 0.721 0.783(0.36; 1.69) 0.534
Leptin (pg/mL) 3438.1 (154050.1) 5547.6 (22928.2) 0.529 0.93 (0.55; 1.58) 0.795
Resistin (pg/mL) 1233.1 (15063.9) 1070.4 (2795.7) 0.478 0.76 (0.39; 1.47) 0.425
Adiponectin (ng/mL) 662.9 (10917.3) 1226.6 (4993.1) 0.634 1.14 (0.39; 3.31) 0.800
Values expressed as median [interquartile range = upper quartile (Q3) - lower quartile (Q1)] and adjusted arithmetic mean ratio (aAMR) [95% of confidence interval
(95% CI)]. Statistically significant differences are shown in bold. (a)P-values were calculated by generalized linear models (GLM) with gamma distribution (log-link).
(b)P-values were calculated by GLM with log-link adjusted by the most important clinical and epidemiological characteristics (see Statistical analysis section).
Abbreviations: HCV hepatitis C virus, HIV human immunodeficiency virus, HGF hepatic growth factor, NGF nerve growth factor, PAI-1 plasminogen
activator inhibitor-1.
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ence on insulin sensitivity and lipid metabolism [45,46],
which are regulated directly or indirectly by PPARγ2 [47].
The exact mechanism by which the rs1801282 poly-
morphism acts is not well understood, but Ala variant at
PPARγ2 gene seems to be an important modulator in
metabolic control in the body [7]. In this respect, Ala vari-
ant at PPARγ2 gene seems to reduce transcriptional activ-
ity of PPARγ2 gene, resulting in lower transcription levels
of genes activated by PPAR γ2 and decreasing the process
of inflammation and cardiovascular disease [10,12-15]. In
addition, the functional effect of rs1801282 evaluated in
silico has shown that the Alanine variant may affect pro-
tein function [48]. Therefore, PPARγ2 rs1801282 poly-
morphism could affect the adipokines delivery, since
an increase in PPARγ gene expression generates the
up-regulation of the insulin-sensitizing factor (adiponec-
tin) and down-regulation of insulin-resistant factor (leptin
and TNF-α) [47], as well as, a less efficient stimulation of
PPARγ activated genes predisposing people to lower levels
of adipose tissue mass accumulation [49].
Metabolic disorders are closely related to chronic in-
flammatory response, characterized by abnormal adipo-
kine production, and the activation of proinflammatory
signaling pathways, which may play a central role in the
cardiovascular pathophysiology [50]. The HGF and NGF
are considered adipokines with a possible link to meta-
bolic disorders and other inflammatory-related diseases.
HGF and NGF blood levels are elevated in obese subjects
and are associated with the presence of metabolic syn-
drome and T2DM, and both molecules have been de-
scribed as an inflammatory response protein made by
adipocytes [51]. HGF expression, in adipose tissue, is
inhibited by NF-κB through suppression of PPARγ func-
tion in the HGF gene promoter and PPAR-γ agonists in-
duce HGF expression [52]. In addition, PPAR-γ agonists
may also induce NGF expression [53]. In our study, the
presence of rs1801282 CG/GG genotype was associated
with low serum levels of HGF and NGF, possibly due tothe effect of Ala variant on the decreased expression of
PPARγ2 gene, which decrease the process of inflammation
and cardiovascular disease [10,12-15]. HGF is a powerful
mitogen for hepatocytes and other epithelial tissues
mainly produced by perivascular fat cells [54], and plays a
special role because it is both a very potent angiogenic
growth factor and a cytokine involved in hematopoiesis
and vasculogenesis [55,56]. In addition, NGF is a small
soluble protein (neurotrophin) that is secreted by various
tissues in the body, and it promotes the growth of nerve
cell processes and survival of neurons [57]. NGF seems to
play a role in several diseases related to cardiovascular
risk, such as coronary atherosclerosis, obesity, T2DM, and
metabolic syndrome [58].
We have used the same cohort to publish several gen-
etic association studies between SNPs and metabolic dis-
turbances. The SNPs were selected from a review of
Staiger et al. about the type 2 diabetes risk genes and
their genetic variants in patients not infected with HIV
and/or HCV [36], and our approach was to evaluate
whether these SNPs also might be markers of metabolic
alterations in HIV/HCV coinfected population. Therefore,
although we have performed multiple tests, we have not
conducted a random search of a meaningful result be-
cause these SNPs have been evaluated in general popula-
tion [36]. Thus, these results should not be affected by
adjusting the “p-value” after multiple tests because our
study was a clinical-orientated study [59,60].
There are also other issues that have to be considered
for a correct interpretation of our data. First, this is a
cross-sectional study with a limited number of patients,
which could limit achieving statistically significant values.
Secondly, metabolic disturbance may be caused by several
interacting genetic and environmental determinants, being
complicated to find the true individual effects of each
disease-associated factor. In this regard, we did not have
data on some extra factors that may influence on lipid
levels and insulin resistance such as exercise habits, diet,
lipodystrophy, and alcohol intake. Thirdly, our study
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patients in order to evaluate the significance of only chronic
hepatitis C, and in HIV-monoinfected patients in order to
evaluate the significance of HIV infection and cART in the
development of metabolic disturbances. Fourthly, cART
may increase the risk for unfavorable cardiometabolic
profile [2]; but in our study, cART characteristics were in-
cluded in the adjusted regression analyses (see Statistical
analysis section). Furthermore, the number of patients tak-
ing efavirenz in the rs1801282 CC group was significantly
higher than that in the rs1801282 CG/GG group; but we
did not find any significant associations among lipid levels
and HOMA-IR values with efavirenz (data not shown).
Fifthly, the patients selected for our study were patients
who met a set of criteria for starting HCV treatment and it
is possible that this may have introduced a selection bias.
Conclusions
The presence of rs1801282 G allele (Ala variant) was re-
lated to a protective cardiometabolic risk profile in HIV/
HCV coinfected patients. Thus, PPARγ2 rs1801282 poly-
morphism may play a significant role in the development
of metabolic disorders in HIV/HCV coinfected patients,
and might have an influence on the cardiovascular risk.
However, we consider that further analyses are needed in
order to determine the potential use of rs1801282 poly-
morphism as a marker of cardiovascular risk in HIV/
HCV-coinfected patients.
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